Detalles de la búsqueda
1.
Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
J Rheumatol
; 51(4): 415-422, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914221
2.
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
Br J Dermatol
; 187(3): 438-441, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35257363
3.
Clinical and radiographic outcomes at 2â years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
Ann Rheum Dis
; 74(1): 35-43, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25169728
4.
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
Rheumatol Ther
; 9(3): 935-955, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305260
5.
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Adv Ther
; 37(6): 2865-2883, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32378070
6.
Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Arthritis Care Res (Hoboken)
; 69(10): 1484-1494, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28622454
7.
Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.
J Rheumatol
; 43(11): 1997-2009, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27803341
8.
Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial.
Arthritis Care Res (Hoboken)
; 67(12): 1762-6, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26037777
9.
Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
Clin Rheumatol
; 34(3): 563-71, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25604316
10.
Erratum to: Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
Clin Rheumatol
; 34(7): 1321, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25943189
Resultados
1 -
10
de 10
1
Próxima >
>>